KO-539 Menin-KMT2A (MLL) inhibitor Phase ½ R/R AML with NPM1 Mutation) A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemi